341 related articles for article (PubMed ID: 32716740)
1. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Joly F; Hajri T; Maucort-Boulch D; Bin S; Rousset P; Devouassoux-Shisheboran M; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Langlois-Jacques C; Mercier C; Villeneuve L; Freyer G; Golfier F
J Clin Oncol; 2020 Sep; 38(27):3129-3137. PubMed ID: 32716740
[TBL] [Abstract][Full Text] [Related]
2. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Floquet A; Hajri T; Descargues P; Langlois-Jacques C; Bin S; Villeneuve L; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Dherret G; Gerentet C; Rousset P; Freyer G; Golfier F
Gynecol Oncol; 2023 Jan; 168():62-67. PubMed ID: 36401942
[TBL] [Abstract][Full Text] [Related]
3. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
5. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
6. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
[TBL] [Abstract][Full Text] [Related]
7. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group-174 Phase III Trial.
You B; Deng W; Hénin E; Oza A; Osborne R
Int J Gynecol Cancer; 2016 Jan; 26(1):208-15. PubMed ID: 26569059
[TBL] [Abstract][Full Text] [Related]
9. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
11. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
Cheng H; Zong L; Kong Y; Wang X; Gu Y; Cang W; Zhao J; Wan X; Yang J; Xiang Y
Lancet Oncol; 2021 Nov; 22(11):1609-1617. PubMed ID: 34624252
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
[TBL] [Abstract][Full Text] [Related]
14. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
15. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
[TBL] [Abstract][Full Text] [Related]
16. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
Baptista AM; Belfort P
Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.
Taylor F; Short D; Winter MC; Tidy J; Savage PM; Sarwar N; Hancock BW; Seckl MJ; Coleman RE
Gynecol Oncol; 2015 Feb; 136(2):258-63. PubMed ID: 25542400
[TBL] [Abstract][Full Text] [Related]
18. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy.
Roberts JP; Lurain JR
Am J Obstet Gynecol; 1996 Jun; 174(6):1917-23; discussion 1923-4. PubMed ID: 8678159
[TBL] [Abstract][Full Text] [Related]
19. Factors related to treatment outcomes in low-risk gestational neoplasia.
Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease.
Mousavi A; Cheraghi F; Yarandi F; Gilani MM; Shojaei H
Int J Gynaecol Obstet; 2012 Jan; 116(1):39-42. PubMed ID: 21996593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
